Our findings are consistent with the view that P-T217, P-T231, P-S262, and P-S396 facilitate tau aggregation, as previously shown in the literature36,45–47, whereas P-T212, P-S237, Ub-K267, and P-S404 prevent tau aggregation48, highlighting potential targets for the development of tauopathy treatments based on kinases, phosphatases, or ubiquitin signalling enzymes. This evidence concerns the gene MAPT and tauopathy.